7月15日，强生盘中下跌3.02%，报246.18美元/股，成交额18.21亿美元。
消息面上，强生于当日盘前公布第二季度财报，调整后每股收益2.90美元超市场预期的2.85美元，营收253.1亿美元超预期的250.5亿美元，同比增长6.6%，并上调全年业绩指引至调整后EPS 11.60-11.75美元、销售额中值1011亿美元。然而，尽管肿瘤学等创新药物板块表现强劲，医疗器械业务增长放缓成为本季拖累因素。此外，公司同期启动供应链重组计划，预计成本6.5亿至7.5亿美元，叠加医疗保健板块整体承压，市场以"利好出尽"逻辑抛售，股价在业绩公布后持续走低。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.